

June 5, 2017



## **iBio, Inc. to Present Plant-Made Pharmaceutical Platform at Plant-Based Vaccines, Antibodies & Biologics Conference**

NEW YORK, June 05, 2017 (GLOBE NEWSWIRE) -- **iBio, Inc.** (NYSE MKT:IBIO), a leader in developing plant-based biopharmaceuticals, announced today that Barry Holtz, PhD, President of iBio CMO LLC is scheduled to present the Company's pharmaceutical development and production platforms during two sessions at the Plant-Based Vaccines, Antibodies & Biologics Conference in Albufeira, Portugal from June 5-7.

Details of the Company's plenary presentations are listed below.

### **'cGmp manufacturing of a high molecular weight therapeutic protein-advantages of the PMP platform for downstream separations'**

Monday, June 5, 5:30 PM – 5:50 PM WEST

### **'A path forward for commercial acceptance of PMP: The fully integrated CDMO'**

Tuesday, June 6, 4:05 PM – 4:20 PM WEST

"This international conference provides an important forum to showcase advanced biologic platforms and products, and we look forward to engaging in a productive dialogue across the industry," stated Dr. Holtz. "iBio's presentations further reinforce the advantages of a plant-made pharmaceutical platform to deliver a novel and diverse set of solutions to biopharmaceutical companies, as well as the potential of our therapeutic candidate for fibrosis. Although most of our work for clients is confidential, our customers' interests span a diverse range of product types including antibodies, growth factors, and vaccine antigens. During this conference, we will describe the benefits we offer customers such as these in shortening product development timelines and accelerating the advancement of their valuable product candidates."

### ***About iBio, Inc.***

iBio, a leader in developing plant-based biopharmaceuticals, provides a range of product and process development, analytical, and manufacturing services at the large-scale development and manufacturing facility of its subsidiary iBio CMO LLC in Bryan, Texas. The facility houses laboratory and pilot-scale operations, as well as large-scale automated hydroponic systems capable of growing over four million plants as "in process inventory" and delivering over 300 kilograms of therapeutic protein pharmaceutical active ingredient per year. Facility capacity can be doubled by adding additional plant growth equipment in a

space already reserved for that purpose.

iBio applies its technology for the benefit of its clients and the advancement of its own product interests. The Company's pipeline is comprised of proprietary candidates for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. IBIO-CFB03, based on the Company's proprietary gene expression technology, is the Company's lead therapeutic candidate being advanced for IND development.

Further information is available at: [www.ibioinc.com](http://www.ibioinc.com)

### **FORWARD-LOOKING STATEMENTS**

STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

ICR, Inc. (Investor and Media Inquiries):

Stephanie Carrington  
Tel. +1 646-277-1282  
Stephanie.Carrington@icrinc.com

James Heins  
Tel. +1 203-682-8251  
James.Heins@icrinc.com

Source: iBio, Inc.